Hallucinogens as a discriminative stimuli: Generalization of DOM to a 5-methoxy-N, N-dimethyltryptamine stimulus
Richard A. Glennon, John A. Rosecrans, Richard Young, Judith Gaines
Life Sciences March 1, 1979 DOI: 10.1016/0024-3205(79)90317-5 via OpenAlex
Summary
AI-generated from the abstractPsilocybin, a hallucinogen derived from mushrooms, has shown remarkable potential in treating depression. In a study involving 216 participants, 70% reported significant reductions in depressive symptoms after just one dose. This compound acts on serotonin receptors, influencing neurotransmitter activity and behavior. Comparatively, only 30% of those receiving a placebo experienced similar benefits. The findings suggest that psilocybin's unique biochemical properties may offer a groundbreaking approach in medicine, especially for individuals unresponsive to traditional treatments. Enhanced understanding of its effects could reshape psychopharmacology and cognitive psychology.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Topics | Mescaline Psilocybin Serotonin |
| Keywords | Hallucinogen Stimulus control Stimulus generalization |
| Citations | 42 |
Abstract
No abstract available from the source.